Cookies on this site
This website uses cookies to give you the best experience online and to provide anonymised, aggregated site usage data. You can find out what cookies we use, what they do and how you can disable them in our Cookie Policy. By browsing this website and closing this message, you consent to the use of cookies in accordance with our Cookie Policy unless you have disabled them.

Close this message

Success

Thanks for registering for future updates.
Continue

Burden of Atopic Dermatitis

The chronic, persistent nature of atopic dermatitis (AD) means it’s always there, even when patients may appear asymptomatic.1

Atopic Dermatitis Burden: Debilitating and More Severe When Uncontrolled

  • Characterized by intense itching and recurrent lesions, atopic dermatitis inflicts a substantial physical and mental burden on patients2
  • Patients with moderate to severe atopic dermatitis report potentially debilitating signs and symptoms such as excessive itch, dryness, scaling, and open sores—all of which can lead to pain, sleep disturbance, and impaired social functioning3

Patients with inadequately controlled atopic dermatitis suffer greater physician-rated disease severity and physician-reported burden than those with controlled atopic dermatitis4

Correlation of Atopic Dermatitis Disease Severity With Inadequate Disease Control
graph created by ADKeySuspect.com showing correlation of inadequate ad control and physician-rated severity

 

Disease Burden in Controlled vs Inadequately Controlled Atopic Dermatitis Patients
Graph created by ADKeySuspect.com comparing inadequately controlled vs controlled atopic dermatitis. The graph highlights the impact of inadequately controlled AD on depression, stress, itch, and sleep disturbance.

A chronic and persistent condition, atopic dermatitis can manifest differently in each patient.5

DISCOVER THE UNPREDICTABILITY OF AD

  1. Suárez-Fariñas M, Tintle SJ, Shemer A, et al. Non-lesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127(4):954-964.e1-4.
  2. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-1122.
  3. Silverberg JI, Kantor R. The role of interleukins 4 and/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017;35(3):327-334.
  4. Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol. 2018;45(2):150-157.
  5. Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340-347.